Bursectomy not a recommended standard procedure for cT3-T4a gastric cancer
Japan Researchers found that bursectomy is not a recommended standard procedure for cT3-T4a gastric cancer in D2 gastrectomy in their phase III trial. The Trial results were published in the British Journal of Surgery.
A routine standard procedure in gastrectomy for resectable gastric cancer is the bursectomy where the total resection of the bursa omentalis is done. Researchers from various centers in Japan carried out a phase III trial (JCOG1001) comparing bursectomy and omentectomy alone. It was terminated early at the interim analysis and the final results of the updated analysis after a minimum follow-up of 5 years were reported by the researchers.
A multicenter randomized trial was carried out on patients with histologically proven adenocarcinoma of the stomach (cT3–T4a) between June 2010 and March 2015. They were randomized (1: 1) during surgery to bursectomy or omentectomy-alone groups and then underwent D2 gastrectomy. Nearly 1204 patients were randomized to the two groups having 602 patients in each. The primary endpoint was overall survival. The intention-to-treat basis was used to analyze the overall survival.
The key findings of the study were:
- A significantly higher incidence of Clavien–Dindo grade III–IV intra-abdominal abscess was seen in the bursectomy group than in the omentectomy-alone group (5.5 versus 2.5 percent respectively; P = 0.008).
- The updated 5-year overall survival rates were 74.9% in the bursectomy group and 76.5% in the omentectomy-alone group.
- The adjusted HR for death in the bursectomy group was 1.03 (1-sided P = 0.598).
- Peritoneal recurrence was not decreased by Bursectomy (12.1 versus 12.3 percent respectively; P = 1.000).
- In a multivariable analysis, old age (above 65 years), tumor located in the lower third or posterior wall of the stomach, macroscopic type 3/5, total gastrectomy, and cT4a were independent predictors of poor overall survival, but omentectomy alone was not.
Thus, bursectomy was not recommended as a standard procedure for cT3–T4a gastric cancer in D2 gastrectomy as it did not provide a survival advantage.
Further reading: Kurokawa Y, Doki Y, Mizusawa J, et al. Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001) [published online ahead of print, 2022 Nov 12]. Br J Surg. 2022;znac373. doi: 10.1093/bjs/znac373
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.